Identification of potential antigenic proteins and epitopes for the development of a monkeypox virus vaccine: an in silico approach DOI

Emre Aktaş,

Uğur Sezerman, Murat Özer

et al.

Molecular Diversity, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 15, 2024

Language: Английский

The resurgence of monkeypox clade Ib: a global health emergency and concern DOI
Suresh Kumar, Gunasekaran Subramaniam,

K. J. Senthil Kumar

et al.

Archives of Virology, Journal Year: 2025, Volume and Issue: 170(4)

Published: March 21, 2025

Language: Английский

Citations

1
Monkeypox: A comprehensive review on mutation, transmission, pathophysiology, and therapeutics DOI
Somenath Dutta, Rohan Ghosh,

I. Dasgupta

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 146, P. 113813 - 113813

Published: Dec. 13, 2024

Language: Английский

Citations

5
Mpox: Global epidemic situation and countermeasures DOI Creative Commons

Wen-Shuang Hou,

Nan Wu,

Yanzhi Liu

et al.

Virulence, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 8, 2025

Mpox, is a zoonotic disease caused by the monkeypox virus and primarily endemic to Africa. As countries gradually stop smallpox vaccination, resistance declining, increasing risk of infection with mpox other viruses. On 14 August 2024, World Health Organization announced that spread constituted public health emergency international concern. Mpox's transmission routes symptoms are complex pose new challenges global health. Several vaccines (such as ACAM2000, JYNNEOS, LC16m8, genetically engineered vaccines) antiviral drugs tecovirimat, brincidofovir, cidofovir, varicella immunoglobulin intravenous injection) have been developed marketed prevent control this disease. This review aims introduce epidemic situation, epidemiological characteristics, physiological pathological preventive measures for in detail, provide scientific basis prevention viruses worldwide.

Language: Английский

Citations

0
Epidemiology and Clinical Features of Mpox in Jakarta, Indonesia, August 2022–December 2023 DOI Creative Commons
Hanny Nilasari, Eliza Miranda, Melani Marissa

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 210 - 210

Published: Feb. 20, 2025

Background/Objective: This study explores the epidemiology and clinical features of re-emerging mpox in Jakarta, Indonesia. Methods: used a retrospective design to describe epidemiological data, features, mortality patients from August 2022 December 2023. In addition, this also aims identify differences both people living with HIV (PLHIV) non-HIV (non-PLHIV). Results: Our shows that, as end 2023, 59 cases were treated Jakarta. All Jakarta diagnosed males, mainly found MSM (91.5%), PLHIV (78%). Most would manifest fever, rash, skin lesions. Syphilis was concomitant infection group (22/59, 37.2%). Severe manifestations among without antiretroviral therapy (ART). Conclusions: Mpox all males most them PLHIV. There are various mpox; however, since immunosuppressed could present differently, strong surveillance vaccine notification system, cautious management, spreading vaccination awareness needed prevent treat mpox.

Language: Английский

Citations

0
Mpox: genomic insights and public health implications DOI
Francesco Branda, Massimo Ciccozzi, Fabio Scarpa

et al.

Infectious Diseases, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 7

Published: April 23, 2025

Language: Английский

Citations

0
Identification of potential antigenic proteins and epitopes for the development of a monkeypox virus vaccine: an in silico approach DOI

Emre Aktaş,

Uğur Sezerman, Murat Özer

et al.

Molecular Diversity, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 15, 2024

Language: Английский

Citations

0